SmithKline spins out its orphan assets

Noteworthy

There is a growing realization among the major pharmaceutical companies that even with billion-dollar R&D budgets there always will be research projects that cannot be provided with adequate resources. Moreover, the increasing pressure to find new blockbuster drugs means that short shrift is given to projects unlikely to deliver $300 million-plus annually.

As a result, said Janet Dewdney, formerly director and vice president of biotechnology at SmithKline Beecham (SB) and now founding executive chairman of AdProTech plc, "some projects find themselves at the bottom of the list not because

Read the full 901 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE